澳大利亚地区精神分裂症患者服用抗精神病药依从性的定性研究
Qualitative study on adherence to prescribed antipsychotics in individuals with schizophrenia in regional Victoria, Australia
本研究对澳大利亚维多利亚州地区11名确诊精神分裂症患者进行半结构化访谈,识别出患者坚持服用抗精神病药物的三大主要主题:为避免住院等负面后果而服药、在依赖关系与有限选择中服药、以及将药物视为通往稳定日常生活的途径。研究发现患者依从性多受社会支持网络、对机构化管理的恐惧及生活正常化期望驱动,而不仅仅是出于症状控制,这反映了地区资源受限下的谈判性服药过程。
Introduction
Schizophrenia is defined as a psychotic disorder characterized by disturbances in cognition, emotional responsiveness, and behaviour, distorting the individual’s sense of reality. Typical symptoms reported by individuals with schizophrenia include delusions, hallucinations, disorganized speech, thoughts, and behaviours, as well as negative symptoms such as diminished emotional expression. The World Health Organisation (WHO) (2022) reported that schizophrenia affects 1 in 300 people globally1. Similarly, people with schizophrenia are approximately two to three times more likely to die prematurely than the general population and may experience a reduction in life expectancy of 12–20 years2,3. In the Australian context, schizophrenia affects between 150,000 and 200,000 individuals, ranking as the third leading cause of disability and costing over AUD 2.6 billion dollars in addition to National Disability Insurance Scheme (NDIS) expenditures4,5.
A combination of antipsychotic medications and psychosocial therapy has been found to be the most effective treatment for managing symptoms and improving well-being6. However, studies have shown that individuals with schizophrenia struggle to adhere to their prescribed medications for various reasons, and only about one-third of patients are found to respond well to these medications7,8. The non-adherence rate to antipsychotics is up to 70% among patients with schizophrenia, compared to 50% among those with bipolar affective disorder and 57% among those with anxiety disorders9. Another study reported that 60% of their research participants with schizophrenia discontinued their medication because they believed they no longer required them, while 35% discontinued due to adverse side effects and negative self-esteem10.
Previous studies have shown that medication non-adherence in schizophrenia treatment increases the risk of relapse by five times11 and is associated with a suicide risk 12.4 times higher among individuals with schizophrenia12. Non-adherence also contributes to rehospitalization, exacerbates problems with social and occupational functioning, worsens psychiatric symptoms, and deteriorates cognitive functioning13. Tham et al. claimed that rehospitalization due to medication non-adherence and psychiatric relapse incurred costs of up to USD 1826 million annually for the American government. Additionally, poor therapeutic alliance with the treating team, forgetfulness, negative side effects from antipsychotics, lack of insight, and inadequate family and social support have been identified as contributing factors to non-adherence7,13. Several studies have explored strategies to address medication non-adherence 14,15,16. A trusting therapeutic rapport with the treating team, the level of social and family support, and the least restrictive treatment options have been identified as determinants of improved adherence to medications14.
Over the past decade, the literature has increasingly recognised that medication adherence in schizophrenia is embedded within a broader recovery-oriented, human-rights-based, person-centred, carer-inclusive, and trauma-informed framework of care13,17. Consequently, contemporary research places strong emphasis on autonomy, shared decision‑making, and genuine partnership with service users and their families, rather than on narrow and authoritative notions of “compliance” with antipsychotic medication13. This shift is clearly reflected in legislative reforms such as the Mental Health and Wellbeing Act 2022 in Victoria, Australia, which aims to reduce coercive practices, strengthen supported decision-making, and promote dignity, autonomy, human rights, and least-restrictive, community-based treatment18. Within this context, medication adherence can be understood as a negotiated and relational process that is significantly shaped by the therapeutic alliance between service users and service providers. Mental health professionals are therefore encouraged to foster trust and respect, and to ensure that services align closely with clients’ values, goals, and cultural preferences13. Accordingly, adherence is increasingly conceptualised as a collaborative process rather than a simplistic binary of taking or not taking medication as prescribed.
Furthermore, emerging evidence from Australian metropolitan areas highlights social determinants and geographical inequities, such as housing instability, regional and rural service gaps, financial disadvantages, and social isolation, as influencing factors of antipsychotic medication adherence amongst adults with schizophrenia13,19. The same studies also suggested that people residing outside metropolitan areas may encounter fragmented service pathways, limited specialist services, and reduced access to psychosocial support. These issues can both undermine adherence and intensify pressures to adhere due to limited-service options. However, it is difficult to rely on this existing metropolitan evidence to understand the experiences of individuals residing in regional and remote areas. International qualitative studies have explored the lived experiences of people with schizophrenia in rural and remote communities20,21; however, these findings originate from healthcare systems, social contexts, and geographical environments that differ substantially from those in regional Australia. Even if these studies are considered as a reference, there are limited qualitative enquiries on this subject due to their quantitative outcome measures, while not paying sufficient attention to the lived experiences of adults with schizophrenia from regional and remote communities. Therefore, this study aims to address this pressing literature gap by exploring why adults living with schizophrenia in regional Australia choose to adhere to antipsychotic medications.
While global research extensively documents the causes of medication non-adherence, qualitative studies exploring self-reported motivators for adherence remain scarce, particularly among regional and remote Australian adults with schizophrenia. Without understanding patients’ self-reported motivations, it is difficult to facilitate voluntary adherence to prescribed treatment. This study aims to bridge this gap by exploring the self-reported reasons behind patients’ decisions to take their prescribed antipsychotic medications.
Methodology
Research protocol and ethical considerations
This study was undertaken following the ethical guidelines provided by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Tripartite Guidelines for Good Clinical Practice (GCP) (ICH, 2016). Furthermore, we also considered the National Statement on Ethical Conduct in Human Research (2023), a set of guidelines established under the National Health and Medical Research Council Act 1992. Ethics approval (105324) was obtained from the Saint John of God Hospital and Grampians Health Human Research Ethics Committee on the 12th of March 2024. Research Governance/Side Specific Assessment (SSA) Authorisation to conduct research at Grampians Health was provided on the 15th of April 2024 (Project ID 105324).
The consolidated criteria for reporting qualitative research guidelines (COREQ) were carefully followed while analysing data and reporting the findings.
Inclusion and exclusion criteria
Individuals aged 25–65 years, residing in regional Victoria, with a confirmed diagnosis of schizophrenia who were on maintenance antipsychotic for at least a year with a recorded history of non-adherence and currently case-managed by the Adult Acute Community Mental Health Case Manager were the basic requirements of eligibility. Participants with confirmed or suspected diagnosis of Acquired Brain Injury (ABI), Intellectual Disability (ID), or other neurological impairments that compromise their capacity to make an informed decision were excluded. Patients with Mini-Mental State Examination (MMSE) score lower than 21 or those whose mental state examinations from the past two months indicating impaired cognition, insight and judgment were also excluded. Researchers were not directly involved in participants’ treatment, and participants who were directly treated by researchers were excluded from participation.
Participants information and consent (PICF)
Post-ethics approval, a group orientation about the objective, methodology, significance of the study and the PICF process was offered to treating clinicians during the clinical review meeting of respective department. As initial eligibility screening against the inclusion and exclusion criteria, treating clinician approached the perspective individual and if verbal consent obtained, referral to research team completed. Researcher consulted with respective treating psychiatrist concerning capacity to give a full and informed consent, offered a PICF form and allowed each participant at least one week to consider participation. Eleven participants signed the PICF and completed interview. Suitability to participate in the study was rigorously examined in each stage of contact with the participants. Each participant who completed the semi-structured interview was compensated by a one-off AUD $30 retail/shopping voucher appreciating their contribution. Although participants were currently case managed by the same health organisation where the research team is employed, the researchers were not directly involved in their treatment at the time of recruitment or interview.
Data collection
A total of 47 purposively sampled participants were approached for the study, of whom 21 contacted the researchers expressing interest to participate. Eleven individuals aged 25–65 years with a confirmed diagnosis of schizophrenia who met the inclusion and exclusion criteria were recruited for one-to-one semi-structured interview22. First and third researchers conducted interviews from 15/04/2024 to 10/02/2025. Participants were given the option to complete the interview at the clinic, a community centre, or their own residence. Eight interviews were conducted at the participants’ residences, while the remaining three took place at the clinic. Only interviewer and participant were present during the interview period. Interview had three sections: demographic, experience of medication administration and motivations for adherence to prescribed medications. Interviews were conducted by the principal author and the third author. The average interview time was 54.5 min (range: 30–90 min), and no repeat interviews were warranted. Participants were allowed to take a break if they found talking about medication adherence stressful and triggering traumas; however, this didn’t occur. Example of open-ended questions included: How has your experience of taking your prescribed medications been? What motivates you to take your medications? What are some of the advantages and disadvantages of taking your medications? These questions served as a framework for the interview and follow up questions were also asked. Follow-up questions were used to explore participants’ experiences of treatment decision-making, relationships with family and clinicians, and perceptions of choice and control regarding medication use.
All the interviews were recorded with the help of Microsoft Team Meeting software due to its user friendliness, auto-transcription feature, and convenience of interviewer. The transcripts generated by Microsoft Teams were then compared against the recording as they being proofread by the interviewer. Interviewers also took field notes during the data collection process
Researchers’ reflexivity
The research team comprised a multidisciplinary team of Mental Health Clinicians: a male mental health social worker and academic (first author), a male senior psychologist (second author), a female mental health social worker (third author) and a male consultant psychiatrist and academic (fourth author). Their minimum mental health professional experience was 5 (third author) years, whilst the highest was 20 years (second author). The first and third authors hold a Master of Social Work, the second author holds a Master of Psychology, and the fourth author holds an MD in psychiatry. Collectively, the team brought extensive clinical and academic experiences in working with individuals living in regional Australia with schizophrenia. They also brought varying perspectives of local, clinical, organisational, mental health legal and human rights frameworks, in accordance with state and national guidelines. Although varying experiences facilitated a comprehensive understanding of regional Australian context and lived experiences of participants, the research team recognised that several factors may influence data interpretation. These factors include professional backgrounds, multidisciplinary perspectives, prior assumptions regarding medication adherence, recovery-oriented practice, and mental health service delivery.
Consistent with Braun and Clarke’s Reflexive Thematic Analysis23, multidisciplinary reflexivity was embedded throughout the research process. Researchers met fortnightly, maintained written reflexive journals, and regularly discussed their reflections throughout the research process. The first author facilitated discussions, maintained field notes and reflective memos during data collection and analysis processes. Researchers engaged in ongoing critical reflection regarding personal assumptions, professional experiences and emerging interpretations of the data. This helped critically examine coding decisions, challenge preliminary interpretations, and refine theme development, enabling consideration of the findings from social work, psychology, psychiatric, and academic perspectives. Therefore, reflexivity was exercised as an opportunity to acknowledge and critically examine how researchers’ perspectives influenced the interpretation of participants’ self-reported experiences24.
Data analysis
Braun and Clarke Reflexive Thematic Analysis
Braun and Clarke’s Reflexive Thematic Analysis (RTA) was selected because it offers a flexible yet rigorous approach to examining participants’ subjective experiences and meanings24. The data analysis process was guided by the following six stages of the reflective thematic analysis approach introduced by Brown and Clarke: familiarisation with the data, generating codes, generating themes, reviewing themes, defining and naming themes, and producing the report25. Worked example of Braun and Clarke’s six steps’ approach was followed as guided by Byrne24.
Implementation process
From the very first step of Braun and Clarke’s RTA, i.e. familiarisation with the data, field notes, memos, open-ended questions, and the first draft of the transcriptions were carefully, and multiple times analysed. All members of the research team engaged in ongoing reflexive practice throughout the analytical process, as outlined in Section “Researchers’ reflexivity”. In all authors’ proactive participation and in collaborative efforts, formal coding was completed manually in a paper and then with the help of Microsoft Excel and Word files, guided by the guidelines endorsed by Craun and Clare25. Transcribed interview contents were categorised in excel sheet and after reading line by line, initial codes were formulated that were descriptive and vague. Information that didn’t match the existing codes were labelled as new. Coding was primarily inductive in nature and conducted at a semantic level as recommended by Braun and Clarke’s RTA approach23,26. Codes were reviewed, compared, and iteratively grouped into candidate themes through ongoing interpretive engagement with the dataset24. The analysis was conducted iteratively over an extended period during weekly team meetings, allowing ongoing engagement with the data and refinement of emerging interpretations. In this way, themes were developed through an iterative and interpretive process that examined patterns of meaning across the dataset rather than merely summarising participant responses. Furthermore, the credibility was strengthened through repeated engagement with transcripts, maintenance of field notes and reflexive memos, and regular discussion of developing interpretations among the research team.
The findings were discussed with the participants, who provided positive feedback, and no changes to the findings were required. Additionally, the findings were reviewed with the participants’ mental health treating teams prior to preparing the research report for journal submission.
Findings
Participants characteristics
Eleven participants (five men and six women) voluntarily participated in the study and were recruited between 15 April 2024 and 10 February 2025. The average age of participants was 43 ± 13 years, while the median age was 45 years. The youngest participant was 25 years old and the oldest was 61 years old. The average age of illness onset was ~32 years (range 18–55 years). Ten participants had completed secondary school education, four of whom had completed university studies, while one participant had not completed Year 10. Participants had a median of two previous psychiatric inpatient admissions; four had a history of homelessness; five were estranged from their families; five reported ongoing alcohol and other drug use; five were living in public housing; one was living with family; two were homeless at the time of interview; and three were residing in private rental accommodation.
As outlined in Table 1, three overarching themes were identified from participants’ self-reported experiences of adherence to prescribed antipsychotic medication: adherence as avoidance of adverse consequences; adherence within relationships of dependency and constrained choice; and medication as a pathway to stability and everyday life. While some participants described symptom relief and improved wellbeing as important motivators for adherence, others reported adhering due to fears of hospitalisation, loss of support, interpersonal consequences, and limited autonomy in treatment decision-making.
Adherence as avoidance of adverse consequences
Fear of hospitalisation
Participants reported adhering to their prescribed medications to avoid hospitalisations. Fear of potentially being admitted in inpatient psychiatric facilities was repeatedly reported to be a significant motivator. They described traumatic experiences while being in the ward. Therefore, they preferred to adhere to prescribed medications over the possibility of being involuntarily admitted under the mental health and well-being act. They felt secluded and isolated while being in the inpatient facility.
A respondent said that she preferred dealing with side effects instead of being admitted to the Adult Acute Unit saying, “I don’t want to be put in the AAU. It sucks. It is better to feel sleepy and tired instead of going to the psych ward”. A male participant also reported, “I don’t want to be hospitalised”. We received a similar response from another female participant who mentioned having a history of very traumatic inpatient experience, “He (treating psychiatrist) put me in the psych ward for two weeks. It was lockdown period. I couldn’t see anyone. Very traumatic. I never want to go there again”. Many participants reported taking their prescribed antipsychotic medications out of fear of rehospitalisation.
Worsening psychosocial stresses and fear of relapse
Some reported history of reemergence of psychotic symptoms and inpatient admissions when they tried to self-cease medications. They reported worsening symptoms such as social isolation, loss of employment, relationship breakdown and harm to self and others. One participant said, “If I don’t take, I can’t sleep for 8 days. Medications also help with the voices as well”. Another female participant reported becoming increasingly agitated, angry and acutely distressed; thus, taking medications to avoid adverse consequence. She stated, “because I become very violent towards my family and friends if I do not (take antipsychotics)”.
Adherence within relationships of dependency and constrained choice
Fear of losing support and essential benefits
Many participants described adherence not only as a health-related decision but also as a means of maintaining access to essential supports and services. They reported that adherence was necessary to keep access to NDIS‑funded services, such as community and social participation, self‑care assistance, and capacity‑building programs, and to avoid risking the loss of their Disability Support Pension. One interviewee mentioned, “…not having support system is scary…” and added not wanting to risk losing whatever support systems she has in place by not complying with recommended treatment by her treating team. Another respondent stated that when he didn’t take prescribed medications, he lost transportation support and felt socially isolated. The same participant voiced, “I don’t drive and always must rely on my NDIS support worker or my dad…” and non-adherence risked the continuation of this support. Similarly, two participants shared previous experience of losing Centrelink benefits when they were non-adherent to medications during their manic relapse episodes. One said, “I used to get only four hundred something dollars fortnightly from Centrelink…” and added struggling to afford basics from this limited income. Several participants described adherence in the context of reliance on locally available support services, including NDIS-funded services, transport assistance, and family support. Fear of losing these existing supports was repeatedly described as a significant reason for continuing prescribed treatment.
Limited autonomy and constrained choice
Most participants felt they had little choice or control over their treatment. They reported feeling like their treatment decisions were imposed upon them either by their carers or treating team, which often led to resentment and frustration. Particularly those who were treated under the Community Treatment Order (CTO), reported a lack of autonomy and described adhering to prescribed medications even when not willing to take them to avoid conflicts or negative outcomes.
One interviewee commented, “I just take it. Don’t have other options. If I don’t take it, they will take me to the prison for mad people (referring to psychiatric unit)”. Similar experience was reported by another participant. She reported feeling forced by her father and said, “my dad forced me to go to psych ward even when I had no problem. They never listened to my experiences rather forced their wrong ideas into me and made me sick of it. I never had psychosis, but my dad made the doctor believe I had”. She further added, “regardless of what I believe and what I want, I take them anyway. I have no options”.
Family influence, external pressure and support
Participants frequently described adherence as occurring within relationships involving family members, clinicians, friends, support workers and mental health services. Majority of them reported that some form of support reinforced adherence as prescribed whilst others made them feel adherence as an obligation, and they adhere due to avoid disappointing their families and friends. Therefore, some participants mentioned choosing to take their antipsychotics because of external influence from family members, treating team and support workers. One interviewee said taking medications because “doctor asks me to take them. The voices are quiet, and I can go to Ballarat Central for a walk every day”. Similar experience was reported by another candidate, “my dad and sister convinced me to take it anyway”.
Another participant disclosed feeling abandoned by her family members due to multiple psychotic relapses in the context of self-cessation of medications and taking medications to not lose her ongoing services. She commented, “I don’t want to lose anyone now. I just take what they ask me to do it … I will take it without saying a word back to the”. This suggests that, for some participants, relationships with clinicians, family members, friends, and support services constituted a substantial proportion of their available support within the community. Consequently, some participants described adherence as a means of maintaining these important relationships and support networks.
Participants frequently described medication adherence as driven by fear of clinic follow-up and social embarrassment rather than intrinsic motivation. One participant explained: “I need to go to my GP to get the needle done… If I don’t attend the appointment, I receive a call from the clinic, which is sort of embarrassing…” This participant described attending appointments partly to avoid follow-up contact from services and the embarrassment associated with missed appointments.
Medication adherence as a pathway to stability and everyday life
Perceived benefits and symptom management
Some participants reported administering their prescribed antipsychotics because of experiencing improvement in their overall well-being. They recognised the benefits of taking medications, such as reduction in intensity of perceptual disturbances including auditory as well as visual hallucinations, thought clarity, improved sleep and better social interactions. These perceived benefits reinforced their adherence to prescribed antipsychotics as recommended by their treating team.
A female participant reported taking medications “to feel better and not have these horrible hallucinations”. Another male interviewee also shared a similar experience. He reported hearing voices of a male and a female all the time, who were in prison and were talking to him round the clock via telepathy taking a turn disturbing his sleep and threatening him to hurt him if he adheres to prescribed medications. He said, “I struggled to leave house because they threatened me to kill me if I expose to the sun. Medications helped me to quiet them. Now, they can’t hurt me anymore”. He also added, “they (medications) help me get a good 8 hours sleep and I feel relaxed”. A young female individual also stated taking her monthly depot injection because she found that it contributed in “reducing auditory hallucinations. And, yeah, feeling well. Being able to socialize with my family and my support workers”.
Routine and structure
Those with well-established diagnosis and long history of illness onset reported that antipsychotics administration has become a part of their life, and they are accustomed to the routine of taking them. This includes using webster or blister packs, setting alarms, attending GP and psychiatric review appointments for script, collecting medications from the nearest chemist shop, and having carers around to assist them with medication management. One participant responded, “I wake up, have breakfast, take medications and again take it before I go to bed”. He also added, “I have a webster pack, and they (accommodation staffs) help me take it”.
Leading a normal life
Most participants described adhering to prescribed medication in order to lead what they perceived to be a normal life. In this regard, one female interviewee voiced, “Well, I mean. It can be a little too much at times. I want to get back to work, meet friends and live a normal life”. The hope of regaining normalcy in daily activities, returning to mainstream employment and social life also motivated them to administer antipsychotics as recommended. A male candidate stated taking medications “to be able to do things that I’d like to do more of a social nature with other people because I enjoy social activity”. One of the interviewees also expressed desire to “get back to work, meet friends, and live a normal life” with the help of his prescribed antipsychotics.
Discussion
The findings of this study provide a nuanced understanding on why adult patients with schizophrenia chose to adhere to their prescribed antipsychotic medications. Key motivators included avoiding inpatient admission, preventing adverse consequences, perceived benefits, and limited choice in relation to treatment decisions. These findings are consistent with existing literature, which highlights the complex interactions among personal, social, systemic, and cultural factors influencing medication adherence13,19,27,28.
The findings also highlight that, while adults with schizophrenia residing in regional Australia adhere to their prescribed antipsychotic medications for symptom relief, many described adherences as a negotiated response within a complex therapeutic and social environment. Loss of social support and networks, interpersonal conflict with family members, and ruptures in relationships with family and the treating team were identified as additional drivers of adherence. Many participants also reported having limited choice over the services they receive and consequently experiencing reduced involvement in treatment decision-making. These findings suggest that individuals in regional and remote Australia may experience greater constraints associated with limited-service availability and restricted support options than those residing in metropolitan areas. Adherence therefore appeared embedded within relationships with treating clinicians and broader support systems, which participants perceived as important for maintaining stability, accessing psychosocial support, and improving quality of life.
A particularly noteworthy finding was that many participants reported ongoing adherence despite perceiving limited choice and having little influence over treatment decisions. Several participants described feeling pressured or coerced to take medication, having limited alternatives, and adhering primarily to avoid negative consequences such as involuntary psychiatric admission, conflict with family members, or loss of support. These findings suggest that, despite ongoing emphasis on recovery-oriented practice, many adults with schizophrenia residing in regional Australia continue to experience constrained choice due to limited-service availability and reduced opportunities to participate in treatment decision-making29. This highlights the relevance of the Mental Health and Wellbeing Act 2022 (Vic), which seeks to promote dignity, autonomy, supported decision-making, and human rights within mental health service delivery30. Similarly, these findings reinforce recommendations of the Royal Commission into Victoria’s Mental Health System, which advocated for person-centred care, shared decision-making, reduced compulsory treatment, and greater service-user control over treatment decisions31,32.
The findings also highlight that adherence frequently occurred within relationships involving family members, friends, support workers, and clinicians. Many participants expressed concerns about losing existing supports, including NDIS-funded services, transport assistance, and family support. These findings may be particularly relevant within regional and remote Australian settings, where access to alternative supports and specialist services may be limited13. Consistent with existing literature13,27,28, adherence appeared closely connected to the maintenance of disability-based support structures, social networks, and family relationships rather than solely to perceived therapeutic benefits. While many factors influencing adherence identified in this study have been reported previously, the findings highlight how adherence among adults with schizophrenia in regional Australia is frequently negotiated within contexts of dependency, constrained choice, and reliance on limited support networks.
During the interview process, many participants also reported social and emotional loneliness, estrangement from family members, forgetfulness, and inadequate social support as factors influencing their adherence. Similar findings have been reported in previous studies9,13,27,28,33. As recommended by the Royal Commission into Victoria’s Mental Health System, peer support workers may help address these challenges through fostering social connection, family-inclusive practice, community engagement, and recovery-oriented support34,35. Previous research has also demonstrated that peer support workers can contribute to improved self-management, enhanced hope, greater self-compassion, and improved perceptions of support36. Therefore, strengthening the role of peer support workers within mental health services may support recovery-oriented and least-restrictive care consistent with the intentions of the Mental Health and Wellbeing Act 2022 (Vic)37.
The findings also highlight the importance of addressing social and emotional isolation. Social prescribing, alongside pharmacological intervention, has been proposed as a strategy for improving social connectedness and reducing loneliness38. Although social prescribing has only recently gained attention within Australia, it has been described as a mechanism for strengthening social infrastructure and community participation39,40. However, there remains limited evidence regarding its effectiveness in improving medication adherence among people living with schizophrenia41. Therefore, further research is required to explore whether social prescribing approaches can enhance medication adherence through improving social inclusion and community participation.
Furthermore, the findings highlight the importance of family-inclusive, trauma-informed, and recovery-oriented approaches to care. Many participants described experiences of pressure, coercion, or limited autonomy in treatment decision-making. Previous research has shown that coercive treatment and limited autonomy can undermine therapeutic relationships and adversely affect engagement and recovery; however, collaborative and culturally safe treatment that promotes service users’ preferences can enhance trust and long-term medication adherence42. In culturally diverse societies such as Australia, addressing cultural identity, stigma, and language barriers through co-designed interventions that support active and informed participation by service users, and their carers may improve therapeutic relationships and treatment outcomes43. These findings further reinforce the shift towards relational and rights-based care embedded within the Mental Health and Wellbeing Act 2022 (Vic), which promotes participatory, inclusive, and equitable approaches to mental health care18.
Recent studies have shown that shared decision-making, motivational interviewing, and psychoeducational interventions can improve medication adherence17,44. Improved adherence may reduce the risk of rehospitalisation and support recovery when these interventions are delivered within collaborative and recovery-oriented frameworks17,44. Similarly, digital interventions such as smartphone reminders, text messaging systems, virtual peer check-ins, and electronic medication management tools have demonstrated positive effects on adherence15,45. Although these approaches have shown promise in improving adherence and reducing psychotic symptoms, implementation should remain sensitive to service users’ privacy, autonomy, and preferences16. Incorporating these interventions through collaborative partnerships among multidisciplinary clinicians, service users, and their support networks may help promote empowerment, reduce coercive practices, and support sustainable engagement with treatment46.
Limitations of study and future studies recommendations
This study represents the cross-sectional experiences of eleven participants and focuses solely on regional areas of the state of Victoria, Australia. This small sample size may not reflect the general experiences of the wider population, but the findings are intended to provide an in-depth understanding of participants’ experiences rather than to be statistically generalisable to the wider population. Therefore, the experiences of people living in regional Australia may not reflect those of individuals living in metropolitan areas. However, this study attempts to bridge a significant gap in the literature, as there are only a limited number of studies targeting regional areas. Additionally, the interview guide was designed to broadly explore experiences of medication adherence rather than to specifically examine differences between motivations related to social acceptance, service dependency, and individual self-management. Future studies may benefit from exploring these dimensions in greater depth and comparing experiences across regional and metropolitan settings. This study also recommends future studies should also focus on experiences of Culturally and Linguistically Diverse (CALD) comunities residing in regioanl and rural Australia to explore their experiences with mental health services and antipsychotic medications, as intersectional cultural factors may further influence their service engagement and medication adherence.
Conclusion
The study has provided contextual insight from regional Victoria into why adult patients with schizophrenia adhere to their prescribed antipsychotics and their experiences with prescribed medications. Key motivators identified include motivation to lead a normal life, symptom management, fear of hospitalisation, avoidance of negative consequences and lack of autonomy. This highlights the vital need to integrate lived and living experience workers in mental health settings and the crucial role of mental health social workers to promote human-rights, recovery models, and least-restrictive mental health treatment, as expected by the MHWA 2022 (Vic.). Longitudinal studies to understand the long-term effects of social support systems on medication adherence among individual with schizophrenia is recommended.
The authors recommend expansion of home visits and telehealth, integration of peer support workers, and empowerment of mental health professionals to practice more human rights-based, recovery oriented, shared decision making and least-restrictive treatment approaches. As regional areas are heavily underrepresented in schizophrenia related research and development, respective authorities should invest more in regional mental health research to reinforce further studies.
Data availability
The de-identified datasets generated and analysed during this study are stored securely within the hospital's protected digital system. Due to institutional data governance and privacy restrictions, the datasets are not deposited in a public repository. However, all relevant data supporting the findings of this study are available from the corresponding author (jeevan.bhusal@gh.org.au) upon reasonable request. Requests will be evaluated for scientific validity and data privacy compliance. The expected response timeframe for data requests is 2–4 weeks, and any shared data will be subject to standard data use agreements.
References
World Health Organisation. Schizophrenia, https://www.who.int/news-room/fact-sheets/detail/schizophrenia (2022).
Peritogiannis, V., Ninou, A. & Samakouri, M. Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management. Healthcare 10, 2366 (2022).
Saha, S., Chant, D. & McGrath, J. A Systematic Review of Mortality in Schizophrenia. Arch. Gen. Psychiatry 64, 1123 (2007).
Healthdirect. Schizophrenia. Healthdirect Australia Limited https://www.healthdirect.gov.au/schizophrenia (2024).
Thompson, A. et al. The Australian Early Psychosis Collaborative Consortium (AEPCC): Improving Clinical Care in Early Psychosis. Australas. Psychiatry 31, 306–308 (2023).
Guo, X. et al. Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia. Arch. Gen. Psychiatry 67, 895 (2010).
Teferra, S., Hanlon, C., Beyero, T., Jacobsson, L. & Shibre, T. Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers. BMC Psychiatry 13, 168 (2013).
Kao, Y.-C. & Liu, Y.-P. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects. Compr. Psychiatry 51, 557–565 (2010).
Julius, R. J., Novitsky, M. A. & Dubin, W. R. Medication Adherence: A Review of the Literature and Implications for Clinical Practice. J. Psychiatr. Pract. 15, 34–44 (2009).
Tranulis, C., Goff, D., Henderson, D. C. & Freudenreich, O. Becoming Adherent to Antipsychotics: A Qualitative Study of Treatment-Experienced Schizophrenia Patients. Psychiatr. Serv. 62, 888–892 (2011).
Zhang, H., Mi, W., Li, L., Shi, Y. & Xiao, J. High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s Republic of China. Neuropsychiatr. Dis. Treat. 1161, https://doi.org/10.2147/NDT.S72367 (2015).
Forsman, J., Taipale, H., Masterman, T., Tiihonen, J. & Tanskanen, A. Adherence to psychotropic medication in completed suicide in Sweden 2006–2013: a forensic-toxicological matched case-control study. Eur. J. Clin. Pharmacol. 75, 1421–1430 (2019).
Clifford, L., Crabb, S., Turnbull, D., Hahn, L. & Galletly, C. A qualitative study of medication adherence amongst people with schizophrenia. Arch. Psychiatr. Nurs. 34, 194–199 (2020).
Sendt, K.-V., Tracy, D. K. & Bhattacharyya, S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res 225, 14–30 (2015).
Kim, S. K., Park, S. Y., Hwang, H. R., Moon, S. H. & Park, J. W. Effectiveness of Mobile Health Intervention in Medication Adherence: a Systematic Review and Meta-Analysis. J. Med. Syst. 49, 13 (2025).
Moon, Z. & Walsh, J. Digital interventions in medication adherence: a narrative review of current evidence and challenges. Front. Pharmacol. 16, 1632474 (2025).
Fleischhacker, W. W. The long-term treatment of schizophrenia with antipsychotics: a perennial debate. World Psychiatry 17, 169–170 (2018).
Weller, P. The Human Right to Health and the Mental Health and Wellbeing Act 2022 (Vic). In The Future of Mental Health, Disability and Criminal Law 34–53 (Routledge, 2023).
Tham, X. C. et al. Factors Affecting Medication Adherence Among Adults with Schizophrenia: A Literature Review. Arch. Psychiatr. Nurs. 30, 797–809 (2016).
Coblentz, P. et al. Schizophrenia and metabolic syndrome in rural communities: Understanding barriers and improving care. J. Rural Ment. Health 39, 34–45 (2015).
Reddy, S. et al. Factors influencing access to psychiatric treatment in persons with schizophrenia: A qualitative study in a rural community. Indian J. Psychiatry 56, 54 (2014).
Adeoye-Olatunde, O. A. & Olenik, N. L. Research and scholarly methods: Semi-structured interviews. JACCP 4, 1358–1367 (2021).
Braun, V. & Clarke, V. One size fits all? What counts as quality practice in (reflexive) thematic analysis? Qual. Res. Psychol. 18, 328–352 (2021).
Byrne, D. A worked example of Braun and Clarke’s approach to reflexive thematic analysis. Qual. Quant. 56, 1391–1412 (2022).
Clarke, V. & Braun, V. Thematic analysis. J. Posit. Psychol. 12, 297–298 (2017).
Braun, V. & Clarke, V. Contextualism. thematic analysis a practical guide. (American Psychological Association, 2022).
Ngui, A. N., Vasiliadis, H.-M. & Tempier, R. Factors associated with adherence over time to antipsychotic drug treatment. Clin. Epidemiol. Glob. Health 3, 3–9 (2015).
Guo, J. et al. Influencing factors of medication adherence in schizophrenic patients: a meta-analysis. Schizophrenia 9, 31 (2023).
Tham, S. S. & Solomon, P. Development of a culturally safe recovery-oriented mental health practice. J. Soc. Work Pract. 1–15, https://doi.org/10.1080/02650533.2024.2411050 (2024).
Mental Health and Wellbeing Act 2022 (Vic) (Victoria, 2022).
Donnelly, M. Making the Future Happen: Law Reform Lessons from the Victorian Royal Commission. In The Future of Mental Health, Disability and Criminal Law, 11–33 (Routledge, 2023).
Department of Health. About the final report of the Royal Commission into Victoria’s Mental Health System. https://www.health.vic.gov.au/mental-health-reform/about-the-final-report-of-the-royal-commission-into-victorias-mental-health (2024).
Pothimas, N., Tungpunkom, P. & Kanungpiarn, T. Experiences of medication adherence among people with schizophrenia. JBI Database Syst. Rev. Implement. Rep. 14, 51–57 (2016).
Gillard, S. et al. Describing a principles-based approach to developing and evaluating peer worker roles as peer support moves into mainstream mental health services. Ment. Health Soc. Incl. 21, 133–143 (2017).
Robinson, S. & Isaacs, A. Roles, responsibilities and role challenges of lived experience workers in a regional mental health service: a qualitative study. Adv. Mental Health 1–15, https://doi.org/10.1080/18387357.2024.2436404 (2024).
O’Neill, M. et al. “Whatever journey you want to take, I’ll support you through”: a mixed methods evaluation of a peer worker program in the hospital emergency department. BMC Health Serv. Res. 24, 147 (2024).
Department of Health. Comparison of key provisions: Mental Health and Wellbeing Act 2022 and the Mental Health Act 2014. https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.health.vic.gov.au%2Fsites%2Fdefault%2Ffiles%2F2023-08%2Fcomparison-of-key-provisions-mental-health-and-wellbeing-act-2022-and-mental-health-act-2014-mh.docx&wdOrigin=BROWSELINK (2023).
Reinhardt, G., Vidovic, D. & Hammerton, C. Understanding loneliness: a systematic review of the impact of social prescribing initiatives on loneliness. Perspect. Public Health 141, 204–213 (2021).
Dingle, G. A. et al. Australian and UK Perspectives on Social Prescribing Implementation Research: Theory, Measurement, Resourcing and Discovery to Ensure Health Equity. Health Soc. Care Commun. 2025, (2025).
Aggar, C., Thomas, T., Gordon, C., Bloomfield, J. & Baker, J. Social Prescribing for Individuals Living with Mental Illness in an Australian Community Setting: A Pilot Study. Commun. Ment. Health J. 57, 189–195 (2021).
Cooper, M. et al. Effectiveness and active ingredients of social prescribing interventions targeting mental health: a systematic review. BMJ Open 12, e060214 (2022).
Berring, L. L. et al. Factors and Processes Facilitating Recovery from Coercion in Mental Health Services—A Meta-Ethnography. Healthcare 12, 628 (2024).
Butler, T. et al. A Comprehensive Review of Optimal Approaches to Co-Design in Health with First Nations Australians. Int. J. Environ. Res. Public Health 19, 16166 (2022).
Stratford, A., Brophy, L., Beaton, T. & Castle, D. Recovery, medication and shared responsibility in mental health care. Australas. Psychiatry 21, 550–553 (2013).
Chen, H. H. et al. Efficacy of a Smartphone App in Enhancing Medication Adherence and Accuracy in Individuals With Schizophrenia During the COVID-19 Pandemic: Randomized Controlled Trial. JMIR Ment. Health 10, e50806 (2023).
Reilly, S. et al. Collaborative care approaches for people with severe mental illness. Cochrane Database Syst. Rev. 5, CD009531 (2024).
Acknowledgements
Foremost, the authors acknowledge the traditional custodians of the place of his writing, the Wadawurrung people and pay his respect to Elders past and present. Additionally, we extend our sincere gratitude to foremost all participants for their valuable inputs and Grampians Health, Adult Acute Community Mental Health team for their cooperation and assistance in conceptualising this study. We further extend our gratitude to Rajesh Thankappan, John Woodmansey and Aswin Lal Kizhakkebhagathu, and entire Grampians Health Adult Acute Community Mental Health (South Sector) team for their help in participant recruitment and John Hand for his guidance in ethics application navigation. We are also grateful to Grampians Health Library team for their technical support.
Funding
The first author was awarded AUD 5000 STaRR Seed Grant from Western Alliance for this research project.
Author information
Authors and Affiliations
Federation University, Mt Helen Campus, Ballarat, VIC, Australia
Jeevan Bhusal
Grampians Health Ballarat, Ballarat, VIC, Australia
Jeevan Bhusal, Hamish Molloy, Ashokan Padma Aparna & Dr Nalaka Kolamunna
Central Queensland University, North Rockhampton, QLD, Australia
Jeevan Bhusal
Deakin University, Ballarat, VIC, Australia
Dr Nalaka Kolamunna
Authors
- Jeevan Bhusal
- Hamish Molloy
- Ashokan Padma Aparna
- Dr Nalaka Kolamunna
Contributions
Jeevan Bhusal: Conceptualisation, ethics application preparation, data collection and management, methodology development, data curation, formal analysis, writing original draft, editing, resource management, coordination, communication and journal submission.Hamish Molloy: Conceptualisation, ethics application preparation, methodology development, data curation, formal analysis, editing, and supervision.Ashokan Padma Aparna: Data collection and management, editing and resource management. Dr Nalaka Kolamunna: Methodology development, project oversee, supervision, editing and resource management.
Corresponding author
Correspondence to Jeevan Bhusal.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
Ethics approval (105324) was obtained from the Saint John of God Hospital and Grampians Health Human Research Ethics Committee on the 12th of March 2024. Research Governance/Side Specific Assessment (SSA) Authorisation to conduct research at Grampians Health was provided on the 15th of April 2024 (Project ID 105324).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Bhusal, J., Molloy, H., Aparna, A.P. et al. Qualitative study on adherence to prescribed antipsychotics in individuals with schizophrenia in regional Victoria, Australia. Commun. Health 1, 43 (2026). https://doi.org/10.1038/s44528-026-00050-1
Received: 24 April 2026
Accepted: 01 October 2026
Published: 24 October 2026
Version of record: 24 October 2026
DOI: https://doi.org/10.1038/s44528-026-00050-1
来源:Nature 健康护理主题 · nature.com